恩度联合培美曲塞和顺铂治疗中晚期表皮生长因子受体野生型肺腺癌的近期疗效观察  

Study on the Clinical Effects of Endostar with Pemetrexed and Cisplatin on Advanced-Stage Lung Adenocarcinoma with Wild-Type Epidermal Growth Factor Receptor

作　　者：陈佳佳[1] 曾越灿[1] 吴荣[1] CHEN Jiajia;ZENG Yuecan;WU Rong(Department of Oncology,Shengjing Hospital,China Medical University,Shenyang 110022,China)

机构地区：[1]中国医科大学附属盛京医院肿瘤科,沈阳110022

出　　处：《中国医科大学学报》2019年第4期346-348,353,共4页Journal of China Medical University

摘　　要：目的观察恩度联合培美曲塞+顺铂治疗中晚期表皮生长因子受体(EGFR)野生型肺腺癌的近期疗效及不良反应。方法选择48例中晚期EGFR野生型肺腺癌患者,随机分为观察组和对照组,2组均给予培美曲塞+顺铂化疗:培美曲塞500 mg/m^2,d1,顺铂75 mg/m^2,分成3～4 d给药。观察组在化疗基础上应用恩度:化疗前行生理盐水126 mL+恩度90 mg持续72 h静脉泵入,化疗后行生理盐水168 mL+恩度120 mg持续96 h静脉泵入。21 d为1个周期,4个周期后评价疗效及不良反应;随诊1年,比较2组患者的生存率差异。结果观察组有效率(58.3%)及临床获益率(79.2%)均高于对照组(29.2%,50%)(P <0.05);2组患者骨髓抑制、消化道反应等不良反应发生率未见明显差异(P> 0.05);观察组患者1年生存率为91.7%,显著高于对照组(66.7%,P <0.05)。结论恩度联合培美曲塞+顺铂可显著提高中晚期EGFR野生型肺腺患者的疗效及生存率,且不增加不良反应发生率。Objective To investigate the efficacy of endostar with pemetrexed and cisplatin in the treatment of advanced-stage lung adenocarcinoma with wild-type epidermal growth factor receptor(EGFR)and the adverse reactions associated therewith.Methods A total of 48 patients with advanced-stage lung adenocarcinoma and wild-type EGFR were randomly divided into two groups:the control group and treatment group.In both groups,500 mg/m^2 pemetrexed was administered on the first day and 75 mg/m^2 cisplatin was administered with dividing into 3-4 d.Patients in the treatment group received 90 mg endostar,and 126 mL normal saline(NS)was continuously pumped intravenously for 72 h before chemotherapy.After chemotherapy,120 mg endostar and 168 mL NS were continuously pumped intravenously for 96 h.Treatment lasted 21 d and we evaluated efficacy and adverse reactions after four treatment courses.In addition,one-year survival rates were compared between the two groups.Results The response rate(58.3%)and clinical benefit rate(79.2%)of the treatment group were higher than those of the control group(29.2%and 50%,respectively,P<0.05).There were no statistical differences in the type of adverse reaction,such as myelosuppression and gastrointestinal reaction,among others,between the two groups(P>0.05).Furthermore,the one-year survival rate in the treatment group was 91.7%,which was significantly higher than that in the control group(66.7%,P<0.05).Conclusion The clinical efficacy of endostar with pemetrexed and cisplatin in the treatment of advanced-stage lung adenocarcinoma with wild-type EGFR is greater than that of simple chemotherapy and caused no additional adverse reactions.

关 键 词：培美曲塞 恩度 表皮生长因子受体 肺腺癌 

分 类 号：R734.2[医药卫生—肿瘤]